Compare Stocks → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:BKDNASDAQ:BSTCNASDAQ:FLXNNASDAQ:MGTX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBKDBrookdale Senior Living$6.96+1.5%$6.25$3.33▼$7.05$1.32B1.321.84 million shs1.84 million shsBSTCBioSpecifics Technologies$88.53$88.47$42.00▼$89.15$650.25M0.2461,105 shsN/AFLXNFlexion Therapeutics$9.12$9.20$4.30▼$13.66$458.93M1.531.18 million shsN/AMGTXMeiraGTx$4.80+1.9%$5.82$3.49▼$8.35$308.26M1.29153,273 shs74,543 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBKDBrookdale Senior Living+1.70%+5.29%+6.60%+20.86%+63.06%BSTCBioSpecifics Technologies0.00%0.00%0.00%0.00%0.00%FLXNFlexion Therapeutics0.00%0.00%0.00%0.00%0.00%MGTXMeiraGTx-3.09%-5.99%-23.54%-30.22%-12.45%Protect Yourself While There’s Still Time … (Ad)The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBKDBrookdale Senior Living2.597 of 5 stars1.31.00.04.93.81.70.6BSTCBioSpecifics TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AFLXNFlexion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMGTXMeiraGTx4.2526 of 5 stars3.53.00.04.82.51.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBKDBrookdale Senior Living2.50Moderate Buy$7.507.76% UpsideBSTCBioSpecifics TechnologiesN/AN/AN/AN/AFLXNFlexion TherapeuticsN/AN/AN/AN/AMGTXMeiraGTx3.00Buy$25.67434.72% UpsideCurrent Analyst RatingsLatest BKD, FLXN, BSTC, and MGTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2024BKDBrookdale Senior LivingRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$9.003/15/2024MGTXMeiraGTxRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBKDBrookdale Senior Living$3.02B0.44$0.88 per share7.91$2.15 per share3.24BSTCBioSpecifics Technologies$38.19M17.03$3.38 per share26.18$18.42 per share4.81FLXNFlexion Therapeutics$85.55M5.36N/AN/A($0.34) per share-26.82MGTXMeiraGTx$14.02M21.99N/AN/A$2.17 per share2.21Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBKDBrookdale Senior Living-$189.01M-$0.84N/AN/AN/A-6.27%-44.01%-3.75%5/7/2024 (Confirmed)BSTCBioSpecifics Technologies$24.47M$3.3337.5117.60N/A47.43%14.81%14.46%N/AFLXNFlexion Therapeutics-$113.71M-$2.01N/AN/AN/A-100.32%N/A-44.26%N/AMGTXMeiraGTx-$84.03M-$1.47N/A5.33N/A-599.47%-114.33%-42.56%5/9/2024 (Estimated)Latest BKD, FLXN, BSTC, and MGTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2024N/ABKDBrookdale Senior Living-$0.17N/A+$0.17N/AN/AN/A 3/14/2024Q4 2023MGTXMeiraGTx-$0.46-$0.47-$0.01-$1.36$10.13 million$2.04 million2/20/2024Q4 2023BKDBrookdale Senior Living-$0.19-$0.40-$0.21-$0.40N/A$754.48 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBKDBrookdale Senior LivingN/AN/AN/AN/AN/ABSTCBioSpecifics TechnologiesN/AN/AN/AN/AN/AFLXNFlexion TherapeuticsN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBKDBrookdale Senior Living9.400.800.80BSTCBioSpecifics TechnologiesN/A66.2466.24FLXNFlexion TherapeuticsN/A4.384.05MGTXMeiraGTx0.622.382.38OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBKDBrookdale Senior LivingN/ABSTCBioSpecifics Technologies60.34%FLXNFlexion Therapeutics90.01%MGTXMeiraGTx67.48%Insider OwnershipCompanyInsider OwnershipBKDBrookdale Senior Living1.50%BSTCBioSpecifics Technologies15.70%FLXNFlexion Therapeutics9.13%MGTXMeiraGTx9.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBKDBrookdale Senior Living25,200189.34 million186.50 millionOptionableBSTCBioSpecifics Technologies77.35 millionN/ANot OptionableFLXNFlexion Therapeutics25750.32 million45.73 millionOptionableMGTXMeiraGTx41964.22 million57.99 millionOptionableBKD, FLXN, BSTC, and MGTX HeadlinesSourceHeadlineMeiraGTx Holdings plc (NASDAQ:MGTX): Is Breakeven Near?finance.yahoo.com - April 25 at 10:32 AMMeiraGTx to Participate in Upcoming Investor Conferencesglobenewswire.com - April 24 at 4:30 PMMeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conferenceglobenewswire.com - April 18 at 4:30 PMMGTX Apr 2024 12.500 callfinance.yahoo.com - March 17 at 2:29 AMBuy Rating Affirmed: Meiragtx Holdings’ Promising Pipeline and Strategic Partnerships Set Stage for Growthmarkets.businessinsider.com - March 15 at 11:23 PMMGTX Stock Earnings: MeiraGTx Hldgs Beats EPS, Misses Revenue for Q4 2023investorplace.com - March 14 at 10:03 PMRecap: MeiraGTx Hldgs Q4 Earningsbenzinga.com - March 14 at 8:49 PMMeiraGTx Holdings PLC Reports Notable Clinical Progress Amidst Financial Challenges in 2023hk.finance.yahoo.com - March 14 at 3:48 PMMeira Retreats on Financial Figuresbaystreet.ca - March 14 at 10:48 AMMeiraGTx Holdings PLC (MGTX) Reports Q4 Loss, Misses Revenue Estimateszacks.com - March 14 at 10:46 AMMeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updatesglobenewswire.com - March 14 at 8:30 AMMeiraGTx Holdings plc (NASDAQ:MGTX) stock most popular amongst private equity firms who own 28%, while individual investors hold 26%finance.yahoo.com - February 26 at 1:35 PMMGTX Mar 2024 12.500 callfinance.yahoo.com - February 17 at 10:20 AMMeiraGTx: Bota-Vec Program Advancing With Milestones Being Metseekingalpha.com - February 16 at 6:38 PMMeiraGTx Holdings PLC MGTXmorningstar.com - February 15 at 8:13 PMMeiraGTx Holdings: Other Events, Financial Statements And Exhibitscbonds.com - February 15 at 10:12 AMMeiraGTx receives $50 million milestone payment from Janssenthepharmaletter.com - February 14 at 7:52 AMMeiraGTx Announces $50 Million Milestone from Janssen Pharmaceuticalsfinance.yahoo.com - February 13 at 10:56 AMWall Street Analysts Think MeiraGTx Holdings PLC (MGTX) Could Surge 217.92%: Read This Before Placing a Betfinance.yahoo.com - January 10 at 4:20 PMMeiraGTx (MGTX): Strong Industry, Solid Earnings Estimate Revisionsfinance.yahoo.com - January 10 at 11:20 AMWall Street Analysts Believe MeiraGTx Holdings PLC (MGTX) Could Rally 221.78%: Here's is How to Tradefinance.yahoo.com - December 25 at 1:49 PMMeiraGTx Hldgs Stock (NASDAQ:MGTX), Short Interest Reportbenzinga.com - December 24 at 8:21 AMAnalysts’ Opinions Are Mixed on These Healthcare Stocks: NeuroPace (NPCE), Meiragtx Holdings (MGTX) and Jazz Pharmaceuticals (JAZZ)markets.businessinsider.com - December 23 at 12:00 AMMeiraGTx Hldgs Stock (NASDAQ:MGTX) Dividends: History, Yield and Datesbenzinga.com - December 22 at 7:00 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBrookdale Senior LivingNYSE:BKDBrookdale Senior Living Inc. owns, manages, and operates senior living communities in the United States. It operates in three segments: Independent Living, Assisted Living and Memory Care, and Continuing Care Retirement Communities (CCRCs). The Independent Living segment owns or leases communities comprising independent and assisted living units in a single community that are primarily designed for middle to upper income seniors. The Assisted Living and Memory Care segment owns or leases communities consisting of freestanding, multi-story communities and freestanding, single-story communities, which offer housing and 24-hour assistance with activities of daily living for the Company's residents. This segment also operates memory care communities for residents with Alzheimer's and other dementias. The CCRCs segment owns or leases communities that provides various living arrangements, such as independent and assisted living, memory care, and skilled nursing; and services to accommodate various levels of physical ability and healthcare needs. It also manages communities on behalf of others. Brookdale Senior Living Inc. was incorporated in 2005 and is headquartered in Brentwood, Tennessee.BioSpecifics TechnologiesNASDAQ:BSTCBioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware.Flexion TherapeuticsNASDAQ:FLXNFlexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.MeiraGTxNASDAQ:MGTXMeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.